Christoph Correll, MD
Professor of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, New York; Medical Director, Recognition and Prevention Program, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York
Glen Oaks, New York
Treating schizophrenia can be a challenging and often ultimately unsuccessful endeavor due to the disorder’s broad spectrum of symptoms and the persistent struggle with nonadherence. New insights into the pathophysiology of the disorder and receptor pharmacology have led to the emergence of novel antipsychotics and a variety of formulations. This session will provide you with a comprehensive understanding of the biologic rationale, clinical evidence, and side effect profile of all new and emerging agents, as well as actionable strategies to promote patient engagement and adherence necessary for you to optimize your patients’ individual treatment plans and maximize the likelihood of treatment success.
Supported by an educational grant from Alkermes, Inc.